NexImmune
MD - GaithersburgBiotechnology
Focus: NexImmune is an oncology-focused biotech developing nanoparticle-based AIM (Artificial Immune Modulation) therapies and cell therapies for hematologic malignancies. The company operates as a clinical-stage biotech with a specialized platform approach to T cell engineering.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Open Jobs
0
About NexImmune
AI assessmentNot HiringNo open roles listed right now. Follow NexImmune to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Fludarabine
Oropharyngeal CancerClinical Trials (1)
NCT05582590Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
Phase 1Help build intelligence for NexImmune
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.